A person is admitted to the hospital with a stroke, but not much is known about whether or not that patient will undergo neuroimaging.

In a recent study, the use of a stent to repair pulmonary artery stenosis in children and adults with congenital heart disease was successful in the majority of patients, but many also experienced serious complications. The study was published in March in the Journal of the American College of Cardiology.

MIM Software Inc. announced it has received 510(k) U.S. Food and Drug Administration (FDA) clearance to market full MIM products running on tablets through thin client technology such as Citrix.

Medic Vision Imaging Solutions Ltd. announced the U.S. Food and Drug Administration (FDA) clearance of SafeCT-29 to help healthcare facilities achieve compliance as mandated by NEMA XR-29 Smart Dose standard.

PFO occluder, amplatzer
amplatzer, amplatzer PFO occluder, PFO occlusion, RESPECT trial

May 27, 2016 — A U.S. Food and Drug Administration (FDA) panel recommended approval of a transcatheter patent foramen ovale (PFO) occluder to prevent recurrent ischemic stroke in patients who have had a cryptogenic stroke due to a presumed paradoxical embolism.

The FDA’s Circulatory System Devices Panel met May 24 to discuss the merits of a premarket approval (PMA) application for St. Jude Medical’s Amplatzer PFO Occluder System. The panel voted to recommend approval to the FDA, but there were questions about the device and supporting data from several panel members. 
radial access, transradial

(Watch an  October 2019 update on this article with radial adoption rates nearing 50 percent in the U.S. in the VIDEO: Trends in Radial Access for Percutaneous Coronary Interventions)
 

 

Corsens Medical Ltd. announced it has successfully completed filing of a Pre-Marketing Notification (510(k)) with the U.S. Food and Drug Administration (FDA) for its Corsens Cardiac Monitor.

May 26, 2016 — Ligand Pharmaceuticals Inc. announced the acquisition of economic rights to multiple programs owned by CorMatrix. Ligand will pay $17.5 million and in return will receive a portion of revenue (synthetic royalty) from CorMatrix’s existing marketed products and will have the right to receive future synthetic royalties from potential future products.

The LifeBridge Health Cardiovascular Institute, Baltimore, has launched a pilot study to evaluate the potential benefits of a wireless heart monitoring system for patients with moderate to severe heart failure.

Cancer patients at the Carti Cancer Center, Little Rock, Ark., now have access to the latest innovation in diagnostic imaging with Toshiba America Medical Systems Inc.’s Infinix 4-D CT.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now